Indivior shares plunge as it's set to discontinue a key treatment
Indivior shares dip as its key treatments disappoint the market. What happens next?
![Indivior PLC company logo seen displayed on a smart phone](https://cdn.mos.cms.futurecdn.net/Y548EA4X9exF7KVYZZBBZ4-415-80.jpg)
Shares in pharmaceuticals group Indivior plunged by a third last week after the drugmaker slashed its profit guidance and revealed it would discontinue sales of Perseris, its schizophrenia drug, says This is Money.
Indivior, based in the US, moved its primary listing to America last month, but continues to trade on the FTSE 250. It also warned that sales of its opioid addiction treatment Sublocade continue to be weak, due primarily to changes in the extent to which the drug is covered by the US medical system.
The twin setbacks have created a “tornado” that has wrecked Indivior’s share price, says AJ Bell’s Russ Mould, especially since Perseris had been expected to achieve peak sales of $200 million to $300 million.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
![https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748-320-80.jpg)
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
However, Indivior is “no stranger to setbacks since being spun out of Reckitt 10 years ago”. Settlements linked to criminal and civil investigations in recent years have already rattled the company and the stock. As a result, investors with a “nervous disposition” will have jumped ship a long time ago. Only the “thicker-skinned individuals” will have held on, in the hope that “they can see the longer-term prize”.
Indivior shares and revenue
Despite the recent problems, Indivior’s CEO Mark Crossley remains “upbeat” about the long-term outlook for Sublocade, especially given the scale of the US opioid epidemic, “which is now being driven by misuse of fentanyl and other synthetic opioids”, says Amber Murray in City AM.
Crossley reckons that robust underlying demand will mean that sales of Sublocade should still rise by a quarter from current levels, reaching $1 billion by the end of 2025, and should peak at more than $1.5 billion a year. In the very long run, opioid addiction might not be the only source of potential revenue for Indivior, as the company also sees “further opportunity” from the legalisation of cannabis for recreational use in more than 20 states, says Sabela Ojea in The Wall Street Journal.
This is because Indivior’s pipeline includes a treatment for cannabis-use disorder, which is in advanced clinical trials. At the same time, management thinks that moving the primary listing will improve scope for expansion as it will align the firm with its primary customers, the US government, as well as attracting more US investors and analysts.
But while the company should be an “easy sell” to US investors, there’s “little evidence” that it is benefiting from the transatlantic switch, says Aimee Donnellan on Breakingviews. Even before this week’s “shocker”, its forward price/earnings (p/e) multiple had slipped to seven. There also seems to be “minimal” interest among brokers, with the “low-single-digit number of analysts” attending earnings calls “outnumbered by Indivior participants” on occasion.
The group’s “patchy” record means there’s “a danger that investors continue to shun the business and it becomes an unloved US orphan stock”, proving a “cautionary” tale for “other companies looking to relocate across the pond”.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
The best properties for sale for around £500,000
Properties for sale for around £500k – from a Grade II-listed former rectory in County Durham to an early 19th-century chateau in southwest France.
By Natasha Langan Published
-
M&S recovery has momentum: will it stick?
After years of decline, M&S seems to have turned a corner. But is this just a “dead cat bounce”?
By Dr Matthew Partridge Published
-
Small caps: how to ride the recovery wave of UK equities
Professional investor Ken Wotton highlights British small caps that hit the sweet spot of the British equity market
By Ken Wotton Published
-
Investing in defence: the easiest way to buy into the boom
The defence sector has taken off, but the opportunities for stock picking are more limited. We explain what to buy
By Frederic Guirinec Published
-
The investment opportunities in a bear market
As equities fell sharply in August, Max King explores the investment opportunities in a bear market
By Max King Published
-
How to invest in Web 3.0
Here are three core holdings at the forefront of Web 3.0 development that could shape the next era of the internet, according to Chanchal Samadder, head of product at ETC Group
By Chanchal Samadder Published
-
How investors can cash in on undersea cables
Undersea cables are in demand as the renewable energy boom has sparked a race to rewire the world
By Rupert Hargreaves Published
-
Relx outperforms: should you buy this FTSE 100 success story?
Relx, a fast-growing risk management and analytics group is benefiting from artificial intelligence
By Dr Mike Tubbs Published
-
UK stocks have become a global favourite – should you invest?
The world is taking to UK stocks – but how long will it last?
By Alex Rankine Published
-
Beijing targets the boom in bonds
Stocks and property in Beijing have disappointed, but bonds are performing well
By Alex Rankine Published